Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UroCor to launch ProstaSeed in US:

This article was originally published in Clinica

Executive Summary

UroCor is to launch its radioactive source for treatment of prostate cancer, ProstaSeed I-125, throughout the US, with its marketing and distribution partners Mallinckrodt and Prostate Services of America. Oklahoma City, Oklahoma-based UroCor claims to be the only medical company involved in the treatment of prostate cancer with the ability to support both the urologist and the radiation oncologist in diagnosing and managing the patient's condition. Some 200,000 new cases of prostate cancer are diagnosed annually in the US, around 60% of which are potentially treatable by brachytherapy, the company says.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel